News

Thousands of allergy pills recalled

Thousands of allergy pills recalled

RECALLED:Nearly 30,000 allergy tablets are being recalled. Photo: Reuters

MUMBAI (Reuters) – Indian drugmaker Ranbaxy Laboratories Ltd started recalling 29,790 packs of an allergy-relief medicine in the United States in February, after finding defects in the packaging, the U.S. Food and Drug Administration said.

The loratadine and pseudoephedrine sulphate extended release tablets being recalled carry an expiry date of September 2015, and were manufactured by Ranbaxy’s Ohm Labs plant in New Jersey, which is the company’s only facility making generics for the United States.

All other Ranbaxy plants, based in India, have been banned from exporting generics to the United States after the FDA found manufacturing quality glitches that the agency believed could compromise the quality of medicines.

Rival Indian drugmaker Sun Pharmaceutical Industries Ltd agreed to buy Ranbaxy last month in a $3.2 billion deal, betting it can fix Ranbaxy’s problems.

The FDA classified the recall by Ohm Labs as Class II, which means use of or exposure to the recalled products may cause temporary or medically reversible adverse health consequences.

Ranbaxy did not immediately respond to requests for comment.

(Reporting by Zeba Siddiqui in MUMBAI; Editing by Subhranshu Sahu)

Recent Headlines

in Local

One arrested following stabbing in downtown Ithaca

Crime 3

The incident was reported around 1:30 Friday near the intersection of West Buffalo and North Cayuga Streets.

in Sports

This weekend’s sports schedule

cavs

Here's a look at this weekend's sports schedule.

in Local

Part-time IC faculty continue drive to unionize

ithaca college3

Faculty members say a meeting Wednesday with administrators was productive, it's still unclear how the college will handle the situation.

in Sports

This week’s top sports shots

AP53093899001_9

A look at some of this week's biggest plays and best moments in sports.

in National

Making headlines this week

AP125285800932_17

A look back at some of this week's biggest headlines and the stories you may have missed.